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Abstract 
The objective is to report a case of recurrent breast cancer in a poor CYP2D6 metabolizer male patient on tamoxifen, and how 
pharmacogenomic (PGx) testing can play an important role in selecting appropriate adjuvant endocrine therapy.  
 
The case examined here is a 60-year-old white male diagnosed with recurrence of breast cancer. The patient was prescribed tamoxifen 
four years prior as adjuvant endocrine therapy after initial treatment with surgery. PGx testing ordered at the time of recurrence 
revealed patient is a poor metabolizer of CYP2D6, which may decrease the efficacy of tamoxifen. The results prompted a change in 
therapy to an aromatase inhibitor (AI). 
 
This case illustrates the potential benefits of preemptive PGx testing in a male breast cancer patient to assist in selecting appropriate 
adjuvant therapy based on how the patient metabolizes medications. In addition, PGx testing encourages patient involvement by 
emphasizing the association of genetics in determining treatment. The ultimate goal in performing these tests is to individualize 
treatment to improve safety and efficacy while minimizing adverse drug reactions. 
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Introduction 
Pharmacogenomic (PGx) testing identifies genetic variants that 
effect medication metabolism, adverse effects, and efficacy. 
Results of PGx tests provide additional guidance for selecting 
appropriate medication treatment. Currently PGx tests are not 
routinely ordered in breast cancer patients. However, many 
medications used for treatment and supportive care have PGx 
dosing recommendations.1 Breast cancer is one of the more 
prevalent types of cancer, usually affecting females. The risk of 
a male patient getting breast cancer is 1 in 1000, compared to 
1 in 8 for females.2,3 The key differences between breast cancer 
in men and women are seen in Table 1. As depicted in the table, 
staging for both male and female breast cancer is the same. 
Males that present with breast cancer generally have more 
estrogen receptor positive tumors, higher stage, and a lower 
grade.2 Due to the limited number of male breast cancer cases, 
treatment is based on that of female breast cancer.4 For males 
who present with hormone receptor positive breast cancer, 
adjuvant endocrine therapy with tamoxifen is recommended 
for five to ten years.5 Studies have shown an association 
between CYP2D6 poor metabolizer genotypes and increased 
risks of breast cancer recurrence.6,7,8,9,10 Controversy has  
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remained around the topic due to additional trials which did not 
confirm an association.1,11,12 Clinical guidelines provide dosing 
recommendations for tamoxifen based on CYP2D6 
genotypes.13,14  For CYP2D6 poor metabolizers, the guidelines 
recommend using an alternative agent due to potential lack of 
efficacy with tamoxifen.13,14  This case emphasizes the potential 
benefits of preemptive PGx testing by describing a male breast 
cancer patient diagnosed with recurrence of breast cancer 
while on tamoxifen and later found to be a CYP2D6 poor 
metabolizer.  
 
Setting 
The practice setting is a multispecialty tertiary care clinic 
located in Florida. This clinic offers PGx testing, pharmacist 
provided PGx results consultations, medication therapy 
management (MTM) services, and advanced services to 
patients who are referred by physicians. 
 
Case Report 
The subject is a 60-year-old white male who was diagnosed 
with ER/PR+, HER2- breast cancer in 2014. Other listed health 
conditions for this patient are hyperlipidemia and 
hypertension; BMI is 30kg/m2. No current tobacco or alcohol 
use; patient is a former smoker. Current medications are listed 
in Table 2. His family history includes two aunts with breast 
cancer and a brother with pancreatic cancer. In this patient’s 
case, the risk of having cancer increases significantly due to 
having a first-degree relative with cancer.15 Genetic testing was 
negative for pathogenic mutations. In March of 2014, surgical 
pathological examination found that the patient had Invasive 
Ductal Carcinoma grade 3 with two areas being affected. The 
areas measured 1.2 and 1.0 cm respectively. Later that year, the 
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patient underwent a mastectomy and completed adjuvant 
radiation to the left chest wall. He was started on adjuvant 
endocrine therapy with tamoxifen 20 mg daily.  
 
In 2017, the patient returned to the physician after feeling a 
mass along his mastectomy scar line. He was informed of the 
recurrence of breast cancer in his left chest wall. Following that 
diagnosis, the patient transferred his cancer treatment to this 
location. The patient continued tamoxifen therapy, and 
adherence was confirmed by patient interview in which the 
patient stated he rarely missed doses (less than one per 
month). In 2018, the patient had an excisional biopsy which 
confirmed that the patient had a tumor consistent with 
recurrent breast cancer. The patient was scheduled to start 
chemotherapy in January 2019.  
 
PGx testing was ordered by his oncologist to assist in selecting 
treatment and supportive care. When PGx test results were 
returned, a PGx pharmacist consult was ordered by the same 
oncologist to review medications, discuss the PGx results with 
the patient, and provide recommendations to the oncologist. 
PGx testing revealed that the patient is a poor metabolizer of 
CYP2D6 (*4/*4) and a normal metabolizer of CYP3A4. After the 
pharmacist reviewed the PGx test results with the patient, the 
pharmacist recommended to the oncologist to replace 
tamoxifen with an aromatase inhibitor.  The physician started 
the patient on a leuprolide injection, a gonadotropin releasing 
hormone agonist (GnRHa) at the same time the patient started 
adjuvant radiation. GnRHa may be added to an AI in males to 
suppress testicular production of estrogen which is not 
inhibited by aromatase inhibitors.2,16 Once the patient 
completed radiation, he was started on letrozole, an aromatase 
inhibitor, for adjuvant endocrine therapy; consistent with the 
Clinical Pharmacogenetics Implementation Consortium (CPIC) 
recommendation for CYP2D6 poor metabolizers.13 
 
Discussion 
This patient case is unique in that a male patient experiences 
recurrent ER/PR+ breast cancer while taking tamoxifen and is 
determined to be a CYP2D6 poor metabolizer through PGx 
testing at the time of recurrence. Tamoxifen, a selective 
estrogen receptor modulator, competes with estrogen for 
receptors on estrogen receptor positive breast cancer cells and 
is extensively metabolized by multiple pathways. The primary 
metabolic pathway is demethylation mediated by CYP3A4 
followed by oxidation mediated by CYP2D6 to endoxifen, an 
active metabolite. Endoxifen is approximately 100-fold more 
potent than tamoxifen and greatly contributes to the efficacy 
of tamoxifen.17 Poor CYP2D6 metabolizers have been 
associated with higher risk of breast cancer recurrence due to 
decreased efficacy of tamoxifen; however, this finding has not 
been consistently replicated.1,6-11 The conflicting results have 
been attributed to different source DNA used and varying 
genotyping methods which may result in inconsistent 
identification of CYP2D6 alleles.9 The FDA approved a PGx 
section in the prescribing information of tamoxifen, stating the 
impact of CYP2D6 polymorphisms on the efficacy of tamoxifen 
is not well established. However, this is followed by a statement 
that poor CYP2D6 metabolizers do exhibit significantly lower 
endoxifen levels.18 
 
In 2018, CPIC published the first clinical practice guideline for 
using CYP2D6 genotyping to guide tamoxifen therapy.13 The 
guideline addresses tamoxifen dosing and alternatives based 
on CYP2D6 genotype primarily in females. Recommendations 
for alternatives to standard tamoxifen doses in poor CYP2D6 
metabolizers are classified as “strong” based on “high levels of 
evidence.”13 Dosing recommendations for CYP2D6 genotypes 
are also available from the Dutch Pharmacogenetics Working 
Group.14 The majority of trials and the new guidelines have 
been specific to female breast cancer patients; however, a 
study looking at 53 male breast cancer patients with the 
CYP2D6*4 polymorphism (poor metabolizers) showed male 
individuals that were poor metabolizers also had an increased 
probability of breast cancer recurrence.10 
 
As a poor CYP2D6 metabolizer, the lack of efficacy of tamoxifen 
is a possible contributing factor to recurrence of this patient’s 
breast cancer. Additional factors increasing his risk for 
recurrence include family history of breast cancer, staging of 
tumor, lack of adjuvant chemotherapy at initial diagnosis, and 
being a former smoker.5 
 
The patient was prescribed tamoxifen as adjuvant therapy after 
initial diagnosis and treatment with surgery in 2014 at a 
different medical center. PGx testing was not performed at that 
time. The testing may not have been available at that location 
or could have been cost prohibitive at that time. Utilizing 
preemptive PGx at time of initial diagnosis could have detected 
his poor CYP2D6 metabolizer status and directed prescribing of 
an alternative treatment, such as an aromatase inhibitor, which 
may have been more effective.  An alternative to PGx testing 
that has been proposed is adding a GnRHa to tamoxifen.  
Limited data is available to access efficacy of this combination.  
One study demonstrated enhanced estradiol suppression with 
addition of a GnRHa; however, clinical outcomes were not 
reported and the combination had an increase in adverse 
effects.19  Another possible alternative is determining endoxifen 
concentration levels.14,20 However, PGx testing has the benefit 
of allowing appropriate treatment selection earlier in the 
course of therapy. In addition to determining the function of 
CYP2D6, PGx testing most often incorporates a panel of 
pharmacogenes, which can be applied to multiple medications. 
This is beneficial in patients requiring many different 
medications for cancer treatment, pain management, nausea, 
and other supportive care. 
 
In this patient, PGx testing was ordered by oncology after 
diagnosis of recurrence to assist in drug selection for treatment 
and supportive care, and the pharmacist was consulted to 
review the results with the patient. PGx testing was performed 
from a buccal swab sample using a commercial laboratory, 
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which utilizes polymerase chain reaction and single nucleotide 
polymorphism detection. The PGx test panel detects 27 genes, 
including 9 cytochrome P450 genes. Of note, the test detects 
40 CYP2D6 alleles (Table 3). The report provides major, 
moderate, and minimal gene-drug interactions and provides an 
analysis of whether the patient is a poor, intermediate, normal, 
rapid, or ultra-rapid metabolizer of cytochrome P450 enzymes 
included.21 Once a patient undergoes PGx testing, the results 
may be utilized to guide medication selection. Providing 
pharmacist consultation services to interpret and apply PGx 
results may further enhance therapy selection. In the near 
future, with the advances in PGx testing and computer decision 
support software, medications prescribed through the 
electronic medical record will be screened for gene–drug 
interactions (when PGx results are available) and provide 
interaction alerts. However, more complex issues such as drug-
drug-gene and drug-gene-gene interactions will continue to 
benefit from pharmacist consultation services. This will help 
guide the provider in selecting medications and doses that are 
more individualized to the patient. 
 
Conclusion 
Studying this unique case of a poor CYP2D6 metabolizer male 
patient with breast cancer recurrence potentially due to 
pharmacogenomic inability to convert tamoxifen to the active 
metabolite, reveals the potential benefits of PGx testing. The 
CPIC guideline for CYP2D6 and tamoxifen therapy highlights the 
recommendations for alternative medications to be used in 
patients that are CYP2D6 poor and intermediate 
metabolizers.13 PGx testing in males can provide useful 
information which will allow medication therapy to be tailored 
to the individual needs of the patient. This information enables 
physicians and pharmacists to collaborate to develop an 
individualized medication regimen that is safe and effective, 
with the goal of improving medication related outcomes. 
 
 
Declaration of Conflicting Interests: The authors declare that 
there is no conflict of interest. 
 
Abbreviations: 
CPIC = Clinical Pharmacogentics Implementation Consortium 
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GnRHa = Gonadotropin Releasing Hormone agonist 
HER2 = Human Epidermal Growth Factor receptor 2 
MTM = Medication Therapy Management 
Pharmacogenomic = PGx   
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Table 1: Differences in Male and Female Breast Cancer 
Subtype (%) Male Female 
HR +, HER2- 90 71 
HR +, HER2 + 9 12 
HR-, HER2 + <1 5 
HR-, HER2- <1 12 
5-yr overall survival (%) Male Female 
Stage I 87 90 
Stage II 74 82 
Stage III 57 57 
Stage IV 16 19 
Treatment Male Female 
Genetic counseling All patients Selected patients 
Adjuvant endocrine therapy Tamoxifen Tamoxifen, Aromatase Inhibitor, 
Ovarian Suppression (pre-
menopausal) 
     * HER=human epidermal growth factor receptor 
      HR=hormone receptor 
      Giordano, SH. NEJM. 2018; 378:2311-2320 2   
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Table 2: Current Medications 
Medications/dose Indication Pharmacogenomic 
(Relevance/protein) 
Buspirone (Buspar®) 15 mg mouth 
two times a day 
Anxiety S/CYP3A4 
S/CYP3A5 
 
Cyanocobalamin (Vitamin B-12 ®) 
2,500 mg by mouth daily 
Anxiety No PGx application 
Docusate sodium (Colace ®) 100 
mg by mouth two times a day 
Constipation No PGx application 
Losartan (Cozaar®) 100 mg by 
mouth daily 
Hypertension S/CYP2C9 
S/CYP3A4 
S/CYP3A5 
Ondansetron (Zofran®) 4mg by 
mouth 
Nausea S/CYP2D6 
No PGx application 
Pravastatin (Pravachol®) 20 mg by 
mouth 
Hyperlipidemia S/SLCO1B1 
 
Prednisone (Deltasone®) 5 mg by 
mouth 
Inflammation No PGx application 
Sulfasalazine (Azulfidine®) 500 mg 
tabs 
Take 1,000 mg (2 tablets) by 
mouth three times a day 
Rheumatoid arthritis No PGx application 
Tamoxifen (Nolvadex®) 20 mg by 
mouth daily 
Breast cancer S/CYP3A 
S/CYP2D6 
S/CYP2C9 
S/CYP2C19 
S/CYP2B6 
S/SULT1A1 
S/UGT2B7 
S/UGT1A4 
Ascorbic acid (Vitamin C) 1000 mg 
daily 
Immune Support -- 
Super B complex Supplementation -- 
Zinc acetate 
Take one tablet by mouth  
Supplementation -- 
*Unless otherwise noted. 
Abbreviations: ADRs=adverse drug reaction, BBW=black box warning, BG=blood glucose, CBC=complete blood 
count, FDA=food and drug administration, IM=intramuscular, LFT=liver function test, N/V= nausea and vomiting, 
RBC= red blood cell, SC= subcutaneous  
 
 
 
 
 
Table 3: CYP2D6 Tested Alleles 21 
CYP 2D6 *2A, *2, *3, *4, *4J, *4M, *4N, *5, *6, *6C, *7, *8,*9, 
*10, *11, *12, *13, *14A, *14B, *15, *17, *18, *19, 
*29, *31, *34, *35, *36, *39, *41, *42, *59, *61 
 
 
 
 
 
